Eli Lilly announces results from VIVID-2 study
Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...
Pharmabiz1d
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
Nasdaq4d
Lilly Reports Positive Two-Year VIVID-2 Study Results For Omvoh In Crohn's Disease
The findings were based on the VIVID-2 open-label extension study, which is evaluating the e?cacy and safety of Omvoh for up to three years in adults with moderately to severely active Crohn's ...
Morningstar26d
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Placebo included patients switched to treatment with Omvoh at 12 weeks. Omvoh is also being studied in VIVID-2, an ongoing, open-label extension (OLE) study evaluating the efficacy and safety of ...